Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2016, Article ID 3160486, 31 pages
http://dx.doi.org/10.1155/2016/3160486
Review Article

Immunomodulatory Effects Mediated by Dopamine

1Psychiatric Genetics Department, National Institute of Psychiatry “Ramón de la Fuente”, Clinical Research Branch, Calzada México-Xochimilco 101, Colonia San Lorenzo Huipulco, Tlalpan, 14370 Mexico City, Mexico
2Department of Psychoimmunology, National Institute of Psychiatry “Ramón de la Fuente”, Calzada México-Xochimilco 101, Colonia San Lorenzo Huipulco, Tlalpan, 14370 Mexico City, Mexico
3National Institute of Psychiatry “Ramón de la Fuente”, Clinical Research Branch, Calzada México-Xochimilco 101, Colonia San Lorenzo Huipulco, Tlalpan, 14370 Mexico City, Mexico
4Laboratory of Neuroimmunoendocrinology, National Institute of Neurology and Neurosurgery “Manuel Velasco Suárez”, Avenida Insurgentes Sur 3877, La Fama, Tlalpan, 14269 Mexico City, Mexico
5Unidad de Investigación y Desarrollo, Probiomed S.A. de C.V. Cruce de Carreteras Acatzingo-Zumpahuacán S/N, 52400 Tenancingo, MEX, Mexico
6Area of Neurosciences, Department of Biology of Reproduction, CBS, Universidad Autonoma Metropolitana, Unidad Iztapalapa, Avenida San Rafael Atlixco No. 186, Colonia Vicentina, Iztapalapa, 09340 Mexico City, Mexico
7Unidad de Genética de la Nutrición, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Instituto Nacional de Pediatría, Av. del Iman No. 1, Cuarto Piso, 04530 Mexico City, Mexico

Received 15 March 2016; Revised 29 July 2016; Accepted 8 August 2016

Academic Editor: Peirong Jiao

Copyright © 2016 Rodrigo Arreola et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Franco, R. Pacheco, C. Lluis, G. P. Ahern, and P. J. O'Connell, “The emergence of neurotransmitters as immune modulators,” Trends in Immunology, vol. 28, no. 9, pp. 400–407, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Basu and P. S. Dasgupta, “Dopamine, a neurotransmitter, influences the immune system,” Journal of Neuroimmunology, vol. 102, no. 2, pp. 113–124, 2000. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Cosentino and F. Marino, “Adrenergic and dopaminergic modulation of immunity in multiple sclerosis: teaching old drugs new tricks?” Journal of Neuroimmune Pharmacology, vol. 8, no. 1, pp. 163–179, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. G. E. Torres, “The dopamine transporter proteome,” Journal of Neurochemistry, vol. 97, supplement 1, pp. 3–10, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. R. Pacheco, T. Gallart, C. Lluis, and R. Franco, “Role of glutamate on T-cell mediated immunity,” Journal of Neuroimmunology, vol. 185, no. 1-2, pp. 9–19, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. K. F. Atkinson, S. H. Kathem, X. Jin et al., “Dopaminergic signaling within the primary cilia in the renovascular system,” Frontiers in Physiology, vol. 6, article 103, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Arreola, E. Becerril-Villanueva, C. Cruz-Fuentes et al., “Immunomodulatory effects mediated by serotonin,” Journal of Immunology Research, vol. 2015, Article ID 354957, 21 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. Y. Zhang, S. Cuevas, L. D. Asico et al., “Deficient dopamine D2 receptor function causes renal inflammation independently of high blood pressure,” PLoS ONE, vol. 7, no. 6, Article ID e38745, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. D. C. Borcherding, E. R. Hugo, G. Idelman et al., “Dopamine receptors in human adipocytes: expression and functions,” PLoS ONE, vol. 6, no. 9, Article ID e25537, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Cuevas, V. A. Villar, P. A. Jose, and I. Armando, “Renal dopamine receptors, oxidative stress, and hypertension,” International Journal of Molecular Sciences, vol. 14, no. 9, pp. 17553–17572, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. B. Rubí and P. Maechler, “Minireview: new roles for peripheral dopamine on metabolic control and tumor growth: let's seek the balance,” Endocrinology, vol. 151, no. 12, pp. 5570–5581, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. J.-H. Baik, “Dopamine signaling in reward-related behaviors,” Frontiers in Neural Circuits, vol. 7, article 152, 2013. View at Google Scholar · View at Scopus
  13. N. Ben-Jonathan and R. Hnasko, “Dopamine as a prolactin (PRL) inhibitor,” Endocrine Reviews, vol. 22, no. 6, pp. 724–763, 2001. View at Publisher · View at Google Scholar · View at Scopus
  14. J. D. Salamone, M. Pardo, S. E. Yohn, L. Lopez-Cruz, N. SanMiguel, and M. Correa, “Mesolimbic dopamine and the regulation of motivated behavior,” Current Topics in Behavioral Neurosciences, vol. 27, pp. 231–257, 2016. View at Publisher · View at Google Scholar
  15. J.-M. Beaulieu and R. R. Gainetdinov, “The physiology, signaling, and pharmacology of dopamine receptors,” Pharmacological Reviews, vol. 63, no. 1, pp. 182–217, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. J.-M. Beaulieu, S. Espinoza, and R. R. Gainetdinov, “Dopamine receptors—IUPHAR review 13,” British Journal of Pharmacology, vol. 172, no. 1, pp. 1–23, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. G. C. Beck, P. Brinkkoetter, C. Hanusch et al., “Clinical review: immunomodulatory effects of dopamine in general inflammation,” Critical Care, vol. 8, no. 6, pp. 485–491, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. N. Ayala-Lopez, M. Martini, W. F. Jackson et al., “Perivascular adipose tissue contains functional catecholamines,” Pharmacology Research & Perspectives, vol. 2, no. 3, Article ID e00041, 2014. View at Publisher · View at Google Scholar
  19. E. Nagy, I. Berczi, G. E. Wren, S. L. Asa, and K. Kovacs, “Immunomodulation by bromocriptine,” Immunopharmacology, vol. 6, no. 3, pp. 231–243, 1983. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Bergquist, A. Tarkowski, R. Ekman, and A. Ewing, “Discovery of endogenous catecholamines in lymphocytes and evidence for catecholamine regulation of lymphocyte function via an autocrine loop,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 26, pp. 12912–12916, 1994. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Levite, “Nerve-driven immunity. The direct effects of neurotransmitters on T-cell function,” Annals of the New York Academy of Sciences, vol. 917, pp. 307–321, 2000. View at Google Scholar · View at Scopus
  22. I. Berczi, A. Quintanar-Stephano, and K. Kovacs, “Neuroimmune regulation in immunocompetence, acute illness, and healing,” Annals of the New York Academy of Sciences, vol. 1153, pp. 220–239, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. I. J. Elenkov, R. L. Wilder, G. P. Chrousos, and E. S. Vizi, “The sympathetic nerve—an integrative interface between two supersystems: the brain and the immune system,” Pharmacological Reviews, vol. 52, no. 4, pp. 595–638, 2000. View at Google Scholar · View at Scopus
  24. M. Cosentino, E. Rasini, C. Colombo et al., “Dopaminergic modulation of oxidative stress and apoptosis in human peripheral blood lymphocytes: evidence for a D1-like receptor-dependent protective effect,” Free Radical Biology and Medicine, vol. 36, no. 10, pp. 1233–1240, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. G. Barger and H. H. Dale, “Chemical structure and sympathomimetic action of amines,” The Journal of Physiology, vol. 41, no. 1-2, pp. 19–59, 1910. View at Publisher · View at Google Scholar
  26. H. Blaschko, “The activity of l(-)-dopa decarboxylase,” The Journal of Physiology, vol. 101, no. 3, pp. 337–349, 1942. View at Publisher · View at Google Scholar
  27. C. Mannich, W. Jacobsohn, and Hr. C. Mannich, “Über oxyphenyl-alkylamine und dioxyphenyl-alkylamine,” Berichte der Deutschen Chemischen Gesellschaft, vol. 43, no. 1, pp. 189–197, 1910. View at Publisher · View at Google Scholar
  28. G. Barger and P. G. Ewins, “Some phenolic derivatives of beta phenylethyl-amine,” Journal of the Chemical Society, vol. 97, p. 8, 1910. View at Google Scholar
  29. O. Hornykiewicz, “Dopamine miracle: from brain homogenate to dopamine replacement,” Movement Disorders, vol. 17, no. 3, pp. 501–508, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. D. L. Roe, “The discovery of dopamine's physiological importance,” Brain Research Bulletin, vol. 50, no. 5-6, pp. 375–376, 1999. View at Publisher · View at Google Scholar · View at Scopus
  31. C. A. Marsden, “Dopamine: the rewarding years,” British Journal of Pharmacology, vol. 147, supplement 1, pp. S136–S144, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. Å. Bertler and E. Rosengren, “Occurrence and distribution of dopamine in brain and other tissues,” Experientia, vol. 15, no. 1, pp. 10–11, 1959. View at Publisher · View at Google Scholar · View at Scopus
  33. K. M. Ashe, W.-L. Chiu, A. M. Khalifa et al., “Vesicular monoamine transporter-1 (VMAT-1) mRNA and immunoreactive proteins in mouse brain,” Neuroendocrinology Letters, vol. 32, no. 3, pp. 253–258, 2011. View at Google Scholar · View at Scopus
  34. M. K. Sievert, A. R. Hajipour, and A. E. Ruoho, “Specific derivatization of the vesicle monoamine transporter with novel carrier-free radioiodinated reserpine and tetrabenazine photoaffinity labels,” Analytical Biochemistry, vol. 367, no. 1, pp. 68–78, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Carlsson, M. Lindqvist, and T. Magnusson, “3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists,” Nature, vol. 180, no. 4596, p. 1200, 1957. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Carlsson, M. Lindqvist, T. Magnusson, and B. Waldeck, “On the presence of 3-hydroxytyramine in brain,” Science, vol. 127, no. 3296, p. 471, 1958. View at Google Scholar · View at Scopus
  37. H. Sano, “Biochemistry of the extrapyramidal system Shinkei Kennkyu No Shinpo, Advances in Neurological Sciences. (ISSN 0001-8724) Tokyo, October 1960;5:42–48,” Parkinsonism & Related Disorders, vol. 6, no. 1, pp. 3–6, 1960. View at Google Scholar
  38. H. Ehringer and O. Hornykiewicz, “Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system,” Parkinsonism and Related Disorders, vol. 4, no. 2, pp. 53–57, 1998. View at Publisher · View at Google Scholar · View at Scopus
  39. W. Birkmayer and O. Hornykiewicz, “The effect of l-3,4-dihydroxyphenylalanine (=DOPA) on akinesia in parkinsonism,” Parkinsonism and Related Disorders, vol. 4, no. 2, pp. 59–60, 1998. View at Publisher · View at Google Scholar · View at Scopus
  40. C. Leiva, “Madopar: more than 20 years,” Revue Neurologique, vol. 25, no. 148, pp. 1957–1963, 1997. View at Google Scholar
  41. P. J. García Ruiz and E. Meseguer, “Short history of L-Dopa,” Neurologia, vol. 17, no. 4, pp. 214–217, 2002. View at Google Scholar · View at Scopus
  42. E. Tolosa, M. J. Marti, and F. Valldeoriola, “History of levodopa and dopamine agonists in Parkinson's disease treatment,” Neurology, vol. 50, no. 6, supplement 6, pp. S2–S10, 1998. View at Publisher · View at Google Scholar
  43. R. A. Hauser, “Levodopa: past, present, and future,” European Neurology, vol. 62, no. 1, pp. 1–8, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. P. Teismann, K. Tieu, D.-K. Choi et al., “Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 9, pp. 5473–5478, 2003. View at Publisher · View at Google Scholar · View at Scopus
  45. U. Ungerstedt, L. L. Butcher, S. G. Butcher, N.-E. Andén, and K. Fuxe, “Direct chemical stimulation of dopaminergic mechanisms in the neostriatum of the rat,” Brain Research, vol. 14, no. 2, pp. 461–471, 1969. View at Publisher · View at Google Scholar · View at Scopus
  46. J. W. Kebabian and P. Greengard, “Dopamine-sensitive adenyl cyclase: possible role in synaptic transmission,” Science, vol. 174, no. 4016, pp. 1346–1349, 1971. View at Publisher · View at Google Scholar · View at Scopus
  47. J. W. Kebabian, G. L. Petzold, and P. Greengard, “Dopamine-sensitive adenylate cyclase in caudate nucleus of rat brain, and its similarity to the ‘dopamine receptor’,” Proceedings of the National Academy of Sciences of the United States of America, vol. 69, no. 8, pp. 2145–2149, 1972. View at Publisher · View at Google Scholar · View at Scopus
  48. J. W. Kebabian, “Multiple classes of dopamine receptors in mammalian central nervous system: the involvement of dopamine-sensitive adenylyl cyclase,” Life Sciences, vol. 23, no. 5, pp. 479–483, 1978. View at Publisher · View at Google Scholar · View at Scopus
  49. P. F. Spano, S. Govoni, and M. Trabucchi, “Studies on the pharmacological properties of dopamine receptors in various areas of the central nervous system,” Advances in Biochemical Psychopharmacology, vol. 19, pp. 155–165, 1978. View at Google Scholar · View at Scopus
  50. S. Shimada, S. Kitayama, C.-L. Lin et al., “Cloning and expression of a cocaine-sensitive dopamine transporter complementary DNA,” Science, vol. 254, no. 5031, pp. 576–578, 1991. View at Publisher · View at Google Scholar · View at Scopus
  51. J. E. Kilty, D. Lorang, and S. G. Amara, “Cloning and expression of a cocaine-sensitive rat dopamine transporter,” Science, vol. 254, no. 5031, pp. 578–579, 1991. View at Publisher · View at Google Scholar · View at Scopus
  52. B. Giros, S. El Mestikawy, L. Bertrand, and M. G. Caron, “Cloning and functional characterization of a cocaine-sensitive dopamine transporter,” FEBS Letters, vol. 295, no. 1–3, pp. 149–154, 1991. View at Publisher · View at Google Scholar · View at Scopus
  53. T. B. Usdin, E. Mezey, C. Chen, M. J. Brownstein, and B. J. Hoffman, “Cloning of the cocaine-sensitive bovine dopamine transporter,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 24, pp. 11168–11171, 1991. View at Publisher · View at Google Scholar · View at Scopus
  54. B. Giros, S. el Mestikawy, N. Godinot et al., “Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter,” Molecular Pharmacology, vol. 42, no. 3, pp. 383–390, 1992. View at Google Scholar
  55. Physiology or Medicine for 2000-Press Release.
  56. A. Baudry, A. Alleaume-Butaux, S. Dimitrova-Nakov et al., “Essential roles of dopamine and serotonin in tooth repair: functional interplay between odontogenic stem cells and platelets,” Stem Cells, vol. 33, no. 8, pp. 2586–2595, 2015. View at Publisher · View at Google Scholar · View at Scopus
  57. I. Armando, P. Konkalmatt, R. A. Felder, and P. A. Jose, “The renal dopaminergic system: novel diagnostic and therapeutic approaches in hypertension and kidney disease,” Translational Research, vol. 165, no. 4, pp. 505–511, 2015. View at Publisher · View at Google Scholar · View at Scopus
  58. D. S. Goldstein and C. Holmes, “Neuronal source of plasma dopamine,” Clinical Chemistry, vol. 54, no. 11, pp. 1864–1871, 2008. View at Publisher · View at Google Scholar · View at Scopus
  59. G. Eisenhofer, Å. Aneman, P. Friberg et al., “Substantial production of dopamine in the human gastrointestinal tract,” Journal of Clinical Endocrinology and Metabolism, vol. 82, no. 11, pp. 3864–3871, 1997. View at Publisher · View at Google Scholar · View at Scopus
  60. J. L. Willems, W. A. Buylaert, R. A. Lefebvre, and M. G. Bogaert, “Neuronal dopamine receptors on autonomic ganglia and sympathetic nerves and dopamine receptors in the gastrointestinal system,” Pharmacological Reviews, vol. 37, no. 2, pp. 165–216, 1985. View at Google Scholar · View at Scopus
  61. J. Meiser, D. Weindl, and K. Hiller, “Complexity of dopamine metabolism,” Cell Communication and Signaling, vol. 11, article 34, 2013. View at Publisher · View at Google Scholar · View at Scopus
  62. F. Amenta, A. Ricci, I. Rossodivita, R. Avola, and S. K. Tayebati, “The dopaminergic system in hypertension,” Clinical and Experimental Hypertension, vol. 23, no. 1-2, pp. 15–24, 2001. View at Publisher · View at Google Scholar · View at Scopus
  63. P. A. Jose, G. M. Eisner, and R. A. Felder, “Regulation of blood pressure by dopamine receptors,” Nephron, vol. 95, no. 2, pp. p19–p27, 2003. View at Publisher · View at Google Scholar · View at Scopus
  64. C. R. Jackson, G.-X. Ruan, F. Aseem et al., “Retinal dopamine mediates multiple dimensions of light-adapted vision,” The Journal of Neuroscience, vol. 32, no. 27, pp. 9359–9368, 2012. View at Publisher · View at Google Scholar · View at Scopus
  65. D. E. Hernandez, G. A. Mason, C. H. Walker, and J. E. Valenzuela, “Dopamine receptors in human gastrointestinal mucosa,” Life Sciences, vol. 41, no. 25, pp. 2717–2723, 1987. View at Publisher · View at Google Scholar · View at Scopus
  66. A. Maffei, A. M. Segal, J. C. Alvarez-Perez, A. Garcia-Ocaña, and P. E. Harris, “Anti-incretin, anti-proliferative action of dopamine on β-cells,” Molecular Endocrinology, vol. 29, no. 4, pp. 542–557, 2015. View at Publisher · View at Google Scholar · View at Scopus
  67. N. Simpson, A. Maffei, M. Freeby et al., “Dopamine-mediated autocrine inhibitory circuit regulating human insulin secretion in vitro,” Molecular Endocrinology, vol. 26, no. 10, pp. 1757–1772, 2012. View at Publisher · View at Google Scholar · View at Scopus
  68. R. Bhattacharya, S. Sinha, S.-P. Yang et al., “The neurotransmitter dopamine modulates vascular permeability in the endothelium,” Journal of Molecular Signaling, vol. 3, article 14, 2008. View at Publisher · View at Google Scholar · View at Scopus
  69. B. A. Faraj, Z. L. Olkowski, and R. T. Jackson, “Binding of [3H]-dopamine to human lymphocytes: possible relationship to neurotransmitter uptake sites,” Pharmacology, vol. 42, no. 3, pp. 135–141, 1991. View at Publisher · View at Google Scholar · View at Scopus
  70. B. Bondy, M. Ackenheil, R. Elbers, and M. Fröhler, “Binding of 3H-spiperone to human lymphocytes: a biological marker in schizophrenia?” Psychiatry Research, vol. 15, no. 1, pp. 41–48, 1985. View at Publisher · View at Google Scholar · View at Scopus
  71. B. Bondy, M. Ackenheil, and T. Ruppert, “Spiperone binding in lymphocytes: part of a dopamine uptake system?” Annals of the New York Academy of Sciences, vol. 650, pp. 221–225, 1992. View at Publisher · View at Google Scholar · View at Scopus
  72. S. Basu, P. Sarathi Dasgupta, T. Lahiri, and J. Roy Chowdhury, “Uptake and biodistribution of dopamine in bone marrow, spleen and lymph nodes of normal and tumor bearing mice,” Life Sciences, vol. 53, no. 5, pp. 415–424, 1993. View at Publisher · View at Google Scholar · View at Scopus
  73. A. Ricci and F. Amenta, “Dopamine D5 receptors in human peripheral blood lymphocytes: a radioligand binding study,” Journal of Neuroimmunology, vol. 53, no. 1, pp. 1–7, 1994. View at Publisher · View at Google Scholar · View at Scopus
  74. B. Dean, A. J. McAdam, S. Sundram, G. Pavey, L. C. Harrison, and D. L. Copolov, “Identification of a dopamine-binding protein on the membrane of the human platelet,” Biochemical Journal, vol. 287, no. 1, pp. 45–50, 1992. View at Publisher · View at Google Scholar · View at Scopus
  75. C. Prado, F. Contreras, H. González et al., “Stimulation of dopamine receptor D5 expressed on dendritic cells potentiates Th17-mediated immunity,” The Journal of Immunology, vol. 188, no. 7, pp. 3062–3070, 2012. View at Publisher · View at Google Scholar · View at Scopus
  76. B. Basu, C. Sarkar, D. Chakroborty et al., “D1 and D2 dopamine receptor-mediated inhibition of activated normal T cell proliferation is lost in Jurkat T leukemic cells,” The Journal of Biological Chemistry, vol. 285, no. 35, pp. 27026–27032, 2010. View at Publisher · View at Google Scholar · View at Scopus
  77. M. Ferrari, M. Cosentino, F. Marino et al., “Dopaminergic D1-like receptor-dependent inhibition of tyrosine hydroxylase mRNA expression and catecholamine production in human lymphocytes,” Biochemical Pharmacology, vol. 67, no. 5, pp. 865–873, 2004. View at Publisher · View at Google Scholar · View at Scopus
  78. E. J. Meredith, M. J. Holder, A. Rosén et al., “Dopamine targets cycling B cells independent of receptors/transporter for oxidative attack: implications for non-Hodgkin's lymphoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 36, pp. 13485–13490, 2006. View at Publisher · View at Google Scholar · View at Scopus
  79. P. J. Gaskill, L. Carvallo, E. A. Eugenin, and J. W. Berman, “Characterization and function of the human macrophage dopaminergic system: implications for CNS disease and drug abuse,” Journal of Neuroinflammation, vol. 9, article 203, 2012. View at Publisher · View at Google Scholar · View at Scopus
  80. P. J. Gaskill, T. M. Calderon, A. J. Luers, E. A. Eugenin, J. A. Javitch, and J. W. Berman, “Human immunodeficiency virus (HIV) infection of human macrophages is increased by dopamine: a bridge between HIV-associated neurologic disorders and drug abuse,” The American Journal of Pathology, vol. 175, no. 3, pp. 1148–1159, 2009. View at Publisher · View at Google Scholar · View at Scopus
  81. H. Liang, X. Wang, H. Chen et al., “Methamphetamine enhances HIV infection of macrophages,” American Journal of Pathology, vol. 172, no. 6, pp. 1617–1624, 2008. View at Publisher · View at Google Scholar · View at Scopus
  82. W. Zhao, Y. Huang, Z. Liu, B.-B. Cao, Y.-P. Peng, and Y.-H. Qiu, “Dopamine receptors modulate cytotoxicity of natural killer cells via cAMP-PKA-CREB signaling pathway,” PLoS ONE, vol. 8, no. 6, Article ID e65860, 2013. View at Publisher · View at Google Scholar · View at Scopus
  83. M. Cosentino, A. M. Fietta, M. Ferrari et al., “Human CD4+CD25+ regulatory T cells selectively express tyrosine hydroxylase and contain endogenous catecholamines subserving an autocrine/paracrine inhibitory functional loop,” Blood, vol. 109, no. 2, pp. 632–642, 2007. View at Publisher · View at Google Scholar · View at Scopus
  84. J. Kipnis, M. Cardon, H. Avidan et al., “Dopamine, through the extracellular signal-regulated kinase pathway, downregulates CD4+CD25+ regulatory T-cell activity: implications for neurodegeneration,” The Journal of Neuroscience, vol. 24, no. 27, pp. 6133–6143, 2004. View at Publisher · View at Google Scholar · View at Scopus
  85. N. Kustrimovic, E. Rasini, M. Legnaro, F. Marino, and M. Cosentino, “Expression of dopaminergic receptors on human CD4+ T lymphocytes: flow cytometric analysis of naive and memory subsets and relevance for the neuroimmunology of neurodegenerative disease,” Journal of Neuroimmune Pharmacology, vol. 9, no. 3, pp. 302–312, 2014. View at Publisher · View at Google Scholar · View at Scopus
  86. Y. Watanabe, T. Nakayama, D. Nagakubo et al., “Dopamine selectively induces migration and homing of naive CD8+ T cells via dopamine receptor D3,” Journal of Immunology, vol. 176, no. 2, pp. 848–856, 2006. View at Publisher · View at Google Scholar · View at Scopus
  87. Y. Huang, A.-W. Qiu, Y.-P. Peng, Y. Liu, H.-W. Huang, and Y.-H. Qiu, “Roles of dopamine receptor subtypes in mediating modulation of T lymphocyte function,” Neuroendocrinology Letters, vol. 31, no. 6, pp. 782–791, 2010. View at Google Scholar · View at Scopus
  88. F. McKenna, P. J. McLaughlin, B. J. Lewis et al., “Dopamine receptor expression on human T- and B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study,” Journal of Neuroimmunology, vol. 132, no. 1-2, pp. 34–40, 2002. View at Publisher · View at Google Scholar · View at Scopus
  89. M. C. Ghosh, A. C. Mondal, S. Basu et al., “Dopamine inhibits cytokine release and expression of tyrosine kinases, Lck and Fyn in activated T cells,” International Immunopharmacology, vol. 3, no. 7, pp. 1019–1026, 2003. View at Publisher · View at Google Scholar · View at Scopus
  90. M. J. Besser, Y. Ganor, and M. Levite, “Dopamine by itself activates either D2, D3 or D1/D5 dopaminergic receptors in normal human T-cells and triggers the selective secretion of either IL-10, TNFα or both,” Journal of Neuroimmunology, vol. 169, no. 1-2, pp. 161–171, 2005. View at Publisher · View at Google Scholar · View at Scopus
  91. L. Liu, G. Yuan, Z. Cheng, G. Zhang, X. Liu, and H. Zhang, “Identification of the mRNA expression status of the dopamine D2 receptor and dopamine transporter in peripheral blood lymphocytes of schizophrenia patients,” PLoS ONE, vol. 8, no. 9, Article ID e75259, 2013. View at Publisher · View at Google Scholar · View at Scopus
  92. J. Mikulak, L. Bozzo, A. Roberto et al., “Dopamine inhibits the effector functions of activated NK cells via the upregulation of the D5 receptor,” The Journal of Immunology, vol. 193, no. 6, pp. 2792–2800, 2014. View at Publisher · View at Google Scholar · View at Scopus
  93. G. P. Kirillova, R. J. Hrutkay, M. R. Shurin, G. V. Shurin, I. L. Tourkova, and M. M. Vanyukov, “Dopamine receptors in human lymphocytes: radioligand binding and quantitative RT-PCR assays,” Journal of Neuroscience Methods, vol. 174, no. 2, pp. 272–280, 2008. View at Publisher · View at Google Scholar · View at Scopus
  94. F. Amenta, E. Bronzetti, L. Felici, A. Ricci, and S. K. Tayebati, “Dopamine D2-like receptors on human peripheral blood lymphocytes: a radioligand binding assay and immunocytochemical study,” Journal of Autonomic Pharmacology, vol. 19, no. 3, pp. 151–159, 1999. View at Publisher · View at Google Scholar · View at Scopus
  95. Y. Nagai, S. Ueno, Y. Saeki, F. Soga, and T. Yanagihara, “Expression of the D3 dopamine receptor gene and a novel variant transcript generated by alternative splicing in human peripheral blood lymphocytes,” Biochemical and Biophysical Research Communications, vol. 194, no. 1, pp. 368–374, 1993. View at Publisher · View at Google Scholar · View at Scopus
  96. A. Ricci, E. Bronzetti, L. Felici, S. Greco, and F. Amenta, “Labeling of dopamine D3 and D4 receptor subtypes in human peripheral blood lymphocytes with [3H]7-OH-DPAT: a combined radioligand binding assay and immunochemical study,” Journal of Neuroimmunology, vol. 92, no. 1-2, pp. 191–195, 1998. View at Publisher · View at Google Scholar · View at Scopus
  97. T. Ilani, R. D. Strous, and S. Fuchs, “Dopaminergic regulation of immune cells via D3 dopamine receptor: a pathway mediated by activated T cells,” The FASEB Journal, vol. 18, no. 13, pp. 1600–1602, 2004. View at Publisher · View at Google Scholar · View at Scopus
  98. C. Strell, A. Sievers, P. Bastian et al., “Divergent effects of norepinephrine, dopamine and substance P on the activation, differentiation and effector functions of human cytotoxic T lymphocytes,” BMC Immunology, vol. 10, article 62, 2009. View at Publisher · View at Google Scholar · View at Scopus
  99. B. Bondy, S. de Jonge, S. Pander, J. Primbs, and M. Ackenheil, “Identification of dopamine D4 receptor mRNA in circulating human lymphocytes using nested polymerase chain reaction,” Journal of Neuroimmunology, vol. 71, no. 1-2, pp. 139–144, 1996. View at Publisher · View at Google Scholar · View at Scopus
  100. C. Sarkar, S. Das, D. Chakroborty et al., “Cutting edge: stimulation of dopamine D4 receptors induce T cell quiescence by up-regulating Krüppel-like factor-2 expression through inhibition of ERK1/ERK2 phosphorylation,” The Journal of Immunology, vol. 177, no. 11, pp. 7525–7529, 2006. View at Publisher · View at Google Scholar · View at Scopus
  101. N. Takahashi, Y. Nagai, S. Ueno, Y. Saeki, and T. Yanagihara, “Human peripheral blood lymphocytes express D5 dopamine receptor gene and transcribe the two pseudogenes,” FEBS Letters, vol. 314, no. 1, pp. 23–25, 1992. View at Publisher · View at Google Scholar · View at Scopus
  102. A. Ricci, E. Bronzetti, F. Mignini, S. K. Tayebati, D. Zaccheo, and F. Amenta, “Dopamine D1-like receptor subtypes in human peripheral blood lymphocytes,” Journal of Neuroimmunology, vol. 96, no. 2, pp. 234–240, 1999. View at Publisher · View at Google Scholar · View at Scopus
  103. F. Amenta, E. Bronzetti, F. Cantalamessa et al., “Identification of dopamine plasma membrane and vesicular transporters in human peripheral blood lymphocytes,” Journal of Neuroimmunology, vol. 117, no. 1-2, pp. 133–142, 2001. View at Publisher · View at Google Scholar · View at Scopus
  104. F. R. Buttarelli, A. Circella, C. Pellicano et al., “Dopamine transporter immunoreactivity in peripheral blood lymphocytes in multiple system atrophy,” Journal of Neural Transmission, vol. 116, no. 2, pp. 161–165, 2009. View at Publisher · View at Google Scholar · View at Scopus
  105. D. Marazziti, M. Catena Dell'Osso, S. Baroni et al., “Alterations of the dopamine transporter in resting lymphocytes of patients with different psychotic disorders,” Psychiatry Research, vol. 175, no. 1-2, pp. 54–57, 2010. View at Publisher · View at Google Scholar · View at Scopus
  106. B. Caronti, G. Tanda, C. Colosimo et al., “Reduced dopamine in peripheral blood lymphocytes in Parkinson's disease,” NeuroReport, vol. 10, no. 14, pp. 2907–2910, 1999. View at Publisher · View at Google Scholar · View at Scopus
  107. X.-Y. Zhao, S.-W. Cui, X.-Q. Wang, Y.-P. Peng, and Y.-H. Qiu, “Tyrosine hydroxylase expression in CD4+ T cells is associated with joint inflammatory alleviation in collagen type II-induced arthritis,” Rheumatology International, vol. 33, no. 10, pp. 2597–2605, 2013. View at Publisher · View at Google Scholar · View at Scopus
  108. Y.-H. Qiu, C. Cheng, L. Dai, and Y.-P. Peng, “Effect of endogenous catecholamines in lymphocytes on lymphocyte function,” Journal of Neuroimmunology, vol. 167, no. 1-2, pp. 45–52, 2005. View at Publisher · View at Google Scholar · View at Scopus
  109. I. Kokkinou, E. Nikolouzou, A. Hatzimanolis, E. G. Fragoulis, and D. Vassilacopoulou, “Expression of enzymatically active L-DOPA decarboxylase in human peripheral leukocytes,” Blood Cells, Molecules, and Diseases, vol. 42, no. 1, pp. 92–98, 2009. View at Publisher · View at Google Scholar · View at Scopus
  110. I. Kokkinou, E. G. Fragoulis, and D. Vassilacopoulou, “The U937 macrophage cell line expresses enzymatically active l-Dopa decarboxylase,” Journal of Neuroimmunology, vol. 216, no. 1-2, pp. 51–58, 2009. View at Publisher · View at Google Scholar · View at Scopus
  111. R. C. Alaniz, S. A. Thomas, M. Perez-Melgosa et al., “Dopamine β-hydroxylase deficiency impairs cellular immunity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 5, pp. 2274–2278, 1999. View at Publisher · View at Google Scholar · View at Scopus
  112. U. Grimm, A. Knapp, A. Weber, G. Seidlitz, and M. Wehnert, “Detection of phenylalanine hydroxylase activity in leukocytes and fibroblasts,” Biomedica Biochimica Acta, vol. 42, no. 9, pp. 1135–1141, 1983. View at Google Scholar
  113. G. A. Annenkov and E. E. Safronova, “Presence of active phenylalanine hydroxylase in human leukocytes,” Voprosy Meditsinskoj Khimii, vol. 27, no. 2, pp. 266–271, 1981. View at Google Scholar · View at Scopus
  114. G. A. Annenkov, E. E. Safronova, L. M. Gubernieva, and N. M. Volkova, “Detection of phenylalanine hydroxylase activity in human leukocytes and fibroblasts,” Voprosy Meditsinskoj Khimii, vol. 26, no. 6, pp. 723–726, 1980. View at Google Scholar · View at Scopus
  115. B. A. Faraj, Z. L. Olkowski, and R. T. Jackson, “Active [3H]-dopamine uptake by human lymphocytes: correlates with serotonin transporter activity,” Pharmacology, vol. 48, no. 5, pp. 320–327, 1994. View at Publisher · View at Google Scholar · View at Scopus
  116. F. Marino, M. Cosentino, R. Bombelli, M. Ferrari, S. Lecchini, and G. Frigo, “Endogenous catecholamine synthesis, metabolism, storage, and uptake in human peripheral blood mononuclear cells,” Experimental Hematology, vol. 27, no. 3, pp. 489–495, 1999. View at Publisher · View at Google Scholar · View at Scopus
  117. J. D. Erickson, M. K.-H. Schäfer, T. I. Bonner, L. E. Eiden, and E. Weihe, “Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 10, pp. 5166–5171, 1996. View at Publisher · View at Google Scholar · View at Scopus
  118. M. Essand, S. Vikman, J. Grawé et al., “Identification and characterization of a novel splicing variant of vesicular monoamine transporter 1,” Journal of Molecular Endocrinology, vol. 35, no. 3, pp. 489–501, 2005. View at Publisher · View at Google Scholar · View at Scopus
  119. A. Marchese, T. V. Beischlag, T. Nguyen et al., “Two gene duplication events in the human and primate dopamine D5 receptor gene family,” Gene, vol. 154, no. 2, pp. 153–158, 1995. View at Publisher · View at Google Scholar · View at Scopus
  120. T. Nguyen, R. Sunahara, A. Marchese, H. H. M. Van Tol, P. Seeman, and B. F. O'Dowd, “Transcription of a human dopamine D5 pseudogene,” Biochemical and Biophysical Research Communications, vol. 181, no. 1, pp. 16–21, 1991. View at Publisher · View at Google Scholar · View at Scopus
  121. D. J. E. Housley, M. Nikolas, P. J. Venta et al., “SNP discovery and haplotype analysis in the segmentally duplicated DRD5 coding region,” Annals of Human Genetics, vol. 73, part 3, pp. 274–282, 2009. View at Publisher · View at Google Scholar · View at Scopus
  122. E. Josefsson, J. Bergquist, R. Ekman, and A. Tarkowski, “Catecholamines are synthesized by mouse lymphocytes and regulate function of these cells by induction of apoptosis,” Immunology, vol. 88, no. 1, pp. 140–146, 1996. View at Publisher · View at Google Scholar · View at Scopus
  123. K. Nakano, T. Higashi, R. Takagi, K. Hashimoto, Y. Tanaka, and S. Matsushita, “Dopamine released by dendritic cells polarizes Th2 differentiation,” International Immunology, vol. 21, no. 6, pp. 645–654, 2009. View at Publisher · View at Google Scholar · View at Scopus
  124. K. Nakano, T. Higashi, K. Hashimoto, R. Takagi, Y. Tanaka, and S. Matsushita, “Antagonizing dopamine D1-like receptor inhibits Th17 cell differentiation: preventive and therapeutic effects on experimental autoimmune encephalomyelitis,” Biochemical and Biophysical Research Communications, vol. 373, no. 2, pp. 286–291, 2008. View at Publisher · View at Google Scholar · View at Scopus
  125. J. Bergquist, E. Josefsson, A. Tarkovski, R. Ekman, and A. Ewing, “Measurements of catecholamine-mediated apoptosis of immunocompetent cells by capillary electrophoresis,” Electrophoresis, vol. 18, no. 10, pp. 1760–1766, 1997. View at Publisher · View at Google Scholar · View at Scopus
  126. A. Kavelaars, P. M. Cobelens, M. A. T. Teunis, and C. J. Heijnen, “Changes in innate and acquired immune responses in mice with targeted deletion of the dopamine transporter gene,” Journal of Neuroimmunology, vol. 161, no. 1-2, pp. 162–168, 2005. View at Publisher · View at Google Scholar · View at Scopus
  127. H. González, F. Contreras, C. Prado et al., “Dopamine receptor D3 expressed on CD4+ T cells favors neurodegeneration of dopaminergic neurons duringparkinson's disease,” Journal of Immunology, vol. 190, no. 10, pp. 5048–5056, 2013. View at Publisher · View at Google Scholar · View at Scopus
  128. M. G. García, J. G. Puig, and R. J. Torres, “Adenosine, dopamine and serotonin receptors imbalance in lymphocytes of Lesch-Nyhan patients,” Journal of Inherited Metabolic Disease, vol. 35, no. 6, pp. 1129–1135, 2012. View at Publisher · View at Google Scholar · View at Scopus
  129. M. Giorelli, P. Livrea, and M. Trojano, “Dopamine fails to regulate activation of peripheral blood lymphocytes from multiple sclerosis patients: effects of IFN-β,” Journal of Interferon and Cytokine Research, vol. 25, no. 7, pp. 395–406, 2005. View at Publisher · View at Google Scholar · View at Scopus
  130. M. Zaffaroni, A. Rizzo, S. M. Baldini, A. Ghezzi, and G. Comi, “Induction and add-on therapy with mitoxantrone and Interferon beta in multiple sclerosis,” Neurological Sciences, vol. 29, supplement 2, pp. S230–S232, 2008. View at Publisher · View at Google Scholar · View at Scopus
  131. G. E. A. Brito-Melo, R. Nicolato, A. C. P. de Oliveira et al., “Increase in dopaminergic, but not serotoninergic, receptors in T-cells as a marker for schizophrenia severity,” Journal of Psychiatric Research, vol. 46, no. 6, pp. 738–742, 2012. View at Publisher · View at Google Scholar · View at Scopus
  132. J.-H. Lu, Y.-Q. Liu, Q.-W. Deng, Y.-P. Peng, and Y.-H. Qiu, “Dopamine D2 receptor is involved in alleviation of type II collagen-induced arthritis in mice,” BioMed Research International, vol. 2015, Article ID 496759, 9 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  133. L. Wei, C. Zhang, H. Y. Chen et al., “Dopamine receptor DR2 expression in B cells is negatively correlated with disease activity in rheumatoid arthritis patients,” Immunobiology, vol. 220, no. 3, pp. 323–330, 2015. View at Publisher · View at Google Scholar · View at Scopus
  134. M. Jafari, G. Ahangari, M. Saberi, S. Samangoui, R. Torabi, and M. Zouali, “Distorted expression of dopamine receptor genes in systemic lupus erythematosus,” Immunobiology, vol. 218, no. 7, pp. 979–983, 2013. View at Publisher · View at Google Scholar · View at Scopus
  135. A. E. Taraskina, M. N. Grunina, A. M. R. Zabotina et al., “The key proteins of dopaminergic neurotransmission of human peripheral blood lymphocytes: changed mRNA level in alcohol dependence syndrome,” Bulletin of Experimental Biology and Medicine, vol. 160, no. 2, pp. 271–274, 2015. View at Publisher · View at Google Scholar · View at Scopus
  136. T. Biermann, D. Bönsch, U. Reulbach, J. Kornhuber, and S. Bleich, “Dopamine and N-methyl-D-aspartate receptor expression in peripheral blood of patients undergoing alcohol withdrawal,” Journal of Neural Transmission, vol. 114, no. 8, pp. 1081–1084, 2007. View at Publisher · View at Google Scholar · View at Scopus
  137. N. Vousooghi, S. Z. Zarei, M.-S. Sadat-Shirazi, F. Eghbali, and M. R. Zarrindast, “mRNA expression of dopamine receptors in peripheral blood lymphocytes of computer game addicts,” Journal of Neural Transmission, vol. 122, no. 10, pp. 1391–1398, 2015. View at Publisher · View at Google Scholar · View at Scopus
  138. V. Dias, E. Junn, and M. M. Mouradian, “The role of oxidative stress in Parkinson's disease,” Journal of Parkinson's Disease, vol. 3, no. 4, pp. 461–491, 2013. View at Publisher · View at Google Scholar · View at Scopus
  139. Z. Qi, G. W. Miller, and E. O. Voit, “Computational systems analysis of dopamine metabolism,” PLoS ONE, vol. 3, no. 6, Article ID e2444, 2008. View at Publisher · View at Google Scholar · View at Scopus
  140. T. Hiroi, S. Imaoka, and Y. Funae, “Dopamine formation from tyramine by CYP2D6,” Biochemical and Biophysical Research Communications, vol. 249, no. 3, pp. 838–843, 1998. View at Publisher · View at Google Scholar · View at Scopus
  141. E. Bromek, A. Haduch, K. Gołembiowska, and W. A. Daniel, “Cytochrome P450 mediates dopamine formation in the brain in vivo,” Journal of Neurochemistry, vol. 118, no. 5, pp. 806–815, 2011. View at Publisher · View at Google Scholar · View at Scopus
  142. N. R. Musso, S. Brenci, F. Indiveri, and G. Lotti, “L-tyrosine and nicotine induce synthesis of L-Dopa and norepinephrine in human lymphocytes,” Journal of Neuroimmunology, vol. 74, no. 1-2, pp. 117–120, 1997. View at Publisher · View at Google Scholar · View at Scopus
  143. N. R. Musso, S. Brenci, M. Setti, F. Indiveri, and G. Lotti, “Catecholamine content and in vitro catecholamine synthesis in peripheral human lymphocytes,” The Journal of Clinical Endocrinology & Metabolism, vol. 81, no. 10, pp. 3553–3557, 1996. View at Publisher · View at Google Scholar · View at Scopus
  144. P. Uutela, L. Karhu, P. Piepponen, M. Käenmäki, R. A. Ketola, and R. Kostiainen, “Discovery of dopamine glucuronide in rat and mouse brain microdialysis samples using liquid chromatography tandem mass spectrometry,” Analytical Chemistry, vol. 81, no. 1, pp. 427–434, 2009. View at Publisher · View at Google Scholar · View at Scopus
  145. G. Eisenhofer, M. W. Coughtrie, and D. S. Goldstein, “Dopamine sulphate: an enigma resolved,” Clinical and Experimental Pharmacology & Physiology. Supplement, vol. 26, pp. S41–S53, 1999. View at Google Scholar
  146. N. T. Buu, J. Duhaime, C. Savard, L. Truong, and O. Kuchel, “Presence of conjugated catecholamines in rat brain: a new method of analysis of catecholamine sulfates,” Journal of Neurochemistry, vol. 36, no. 2, pp. 769–772, 1981. View at Publisher · View at Google Scholar · View at Scopus
  147. D. Sulzer and L. Zecca, “Intraneuronal dopamine-quinone synthesis: a review,” Neurotoxicity Research, vol. 1, no. 3, pp. 181–195, 1999. View at Publisher · View at Google Scholar
  148. P. Muñoz, S. Huenchuguala, I. Paris, and J. Segura-Aguilar, “Dopamine oxidation and autophagy,” Parkinson's Disease, vol. 2012, Article ID 920953, 13 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  149. A. Palumbo, M. d'Ischia, G. Misuraca, L. De Martino, and G. Prota, “Iron- and peroxide-dependent conjugation of dopamine with cysteine: oxidative routes to the novel brain metabolite 5-S-cysteinyldopamine,” Biochimica et Biophysica Acta (BBA)—General Subjects, vol. 1245, no. 2, pp. 255–261, 1995. View at Publisher · View at Google Scholar · View at Scopus
  150. D. S. Goldstein, C. Holmes, Y. Sharabi, S. Brentzel, and G. Eisenhofer, “Plasma levels of catechols and metanephrines in neurogenic orthostatic hypotension,” Neurology, vol. 60, no. 8, pp. 1327–1332, 2003. View at Publisher · View at Google Scholar · View at Scopus
  151. L. A. Snyder, J. L. Roberts, and S. C. Sealfon, “Alternative transcripts of the rat and human dopamine D3 receptor,” Biochemical and Biophysical Research Communications, vol. 180, no. 2, pp. 1031–1035, 1991. View at Publisher · View at Google Scholar · View at Scopus
  152. K. Liu, C. Bergson, R. Levenson, and C. Schmauss, “On the origin of mRNA encoding the truncated dopamine D3-type receptor D3nf and detection of D3nf-like immunoreactivity in human brain,” The Journal of Biological Chemistry, vol. 269, no. 46, pp. 29220–29226, 1994. View at Google Scholar · View at Scopus
  153. M. Scarselli, F. Novi, G. U. Corsini, and R. Maggio, “Functional rescue of the inactive splice variant of the dopamine D3 receptor D3nf,” Brain Research, vol. 987, no. 2, pp. 244–247, 2003. View at Publisher · View at Google Scholar · View at Scopus
  154. N. M. Richtand, Y. Liu, R. Ahlbrand, J. R. Sullivan, A. H. Newman, and R. K. McNamara, “Dopaminergic regulation of dopamine D3 and D3nf receptor mRNA expression,” Synapse, vol. 64, no. 8, pp. 634–643, 2010. View at Publisher · View at Google Scholar · View at Scopus
  155. L. M. Pritchard, A. D. Logue, B. C. Taylor et al., “Relative expression of D3 dopamine receptor and alternative splice variant D3nf mRNA in high and low responders to novelty,” Brain Research Bulletin, vol. 70, no. 4–6, pp. 296–303, 2006. View at Publisher · View at Google Scholar · View at Scopus
  156. D. K. Grandy, Y. Zhang, C. Bouvier et al., “Multiple human D5 dopamine receptor genes: a functional receptor and two pseudogenes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 20, pp. 9175–9179, 1991. View at Publisher · View at Google Scholar · View at Scopus
  157. J. M. Vile and P. G. Strange, “D2-like dopamine receptors are not detectable on human peripheral blood lymphocytes,” Biological Psychiatry, vol. 40, no. 9, pp. 881–885, 1996. View at Publisher · View at Google Scholar · View at Scopus
  158. L. Santambrogio, M. Lipartiti, A. Bruni, and R. Dal Toso, “Dopamine receptors on human T- and B-lymphocytes,” Journal of Neuroimmunology, vol. 45, no. 1-2, pp. 113–119, 1993. View at Publisher · View at Google Scholar · View at Scopus
  159. A. Ricci, E. Bronzetti, L. Felici, S. K. Tayebati, and F. Amenta, “Dopamine D4 receptor in human peripheral blood lymphocytes: a radioligand binding assay study,” Neuroscience Letters, vol. 229, no. 2, pp. 130–134, 1997. View at Publisher · View at Google Scholar · View at Scopus
  160. A. J. Harmar, R. A. Hills, E. M. Rosser et al., “IUPHAR-DB: the IUPHAR database of G protein-coupled receptors and ion channels,” Nucleic Acids Research, vol. 37, no. 1, pp. D680–D685, 2009. View at Publisher · View at Google Scholar · View at Scopus
  161. S. P. H. Alexander, A. P. Davenport, E. Kelly et al., “The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors,” British Journal of Pharmacology, vol. 172, no. 24, pp. 5744–5869, 2015. View at Publisher · View at Google Scholar · View at Scopus
  162. S. Brogi, A. Tafi, L. Désaubry, and C. G. Nebigil, “Discovery of GPCR ligands for probing signal transduction pathways,” Frontiers in Pharmacology, vol. 5, article 255, 2014. View at Publisher · View at Google Scholar · View at Scopus
  163. W. M. Oldham and H. E. Hamm, “Heterotrimeric G protein activation by G-protein-coupled receptors,” Nature Reviews Molecular Cell Biology, vol. 9, no. 1, pp. 60–71, 2008. View at Publisher · View at Google Scholar · View at Scopus
  164. G. B. Downes and N. Gautam, “The G protein subunit gene families,” Genomics, vol. 62, no. 3, pp. 544–552, 1999. View at Publisher · View at Google Scholar · View at Scopus
  165. S. Hernádez-López, T. Tkatch, E. Perez-Garci et al., “D2 dopamine receptors in striatal medium spiny neurons reduce L-type Ca2+ currents and excitability via a novel PLCβ1-IP3-calcineurin-signaling cascade,” The Journal of Neuroscience, vol. 20, no. 24, pp. 8987–8995, 2000. View at Google Scholar · View at Scopus
  166. S. Ahn, S. K. Shenoy, H. Wei, and R. J. Lefkowitz, “Differential kinetic and spatial patterns of β-arrestin and G protein-mediated ERK activation by the angiotensin II receptor,” The Journal of Biological Chemistry, vol. 279, no. 34, pp. 35518–35525, 2004. View at Publisher · View at Google Scholar · View at Scopus
  167. S. Amar, G. Shaltiel, L. Mann et al., “Possible involvement of post-dopamine D2 receptor signalling components in the pathophysiology of schizophrenia,” International Journal of Neuropsychopharmacology, vol. 11, no. 2, pp. 197–205, 2008. View at Publisher · View at Google Scholar · View at Scopus
  168. K. A. Harrington, S. J. Augood, A. E. Kingsbury, O. J. F. Foster, and P. C. Emson, “Dopamine transporter (DAT) and synaptic vesicle amine transporter (VMAT2) gene expression in the substantia nigra of control and Parkinson's disease,” Molecular Brain Research, vol. 36, no. 1, pp. 157–162, 1996. View at Publisher · View at Google Scholar · View at Scopus
  169. T. S. Guillot, J. R. Richardson, M. Z. Wang et al., “PACAP38 increases vesicular monoamine transporter 2 (VMAT2) expression and attenuates methamphetamine toxicity,” Neuropeptides, vol. 42, no. 4, pp. 423–434, 2008. View at Publisher · View at Google Scholar · View at Scopus
  170. E. Floor, S. F. Schaeffer, B. E. Feist, and S. E. Leeman, “Synaptic vesicles from mammalian brain: large-scale purification and physical and immunochemical characterization,” Journal of Neurochemistry, vol. 50, no. 5, pp. 1588–1596, 1988. View at Publisher · View at Google Scholar · View at Scopus
  171. W. Lu and M. E. Wolf, “Expression of dopamine transporter and vesicular monoamine transporter 2 mRNAs in rat midbrain after repeated amphetamine administration,” Molecular Brain Research, vol. 49, no. 1-2, pp. 137–148, 1997. View at Publisher · View at Google Scholar · View at Scopus
  172. G. W. Miller, J. D. Erickson, J. T. Perez et al., “Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease,” Experimental Neurology, vol. 156, no. 1, pp. 138–148, 1999. View at Publisher · View at Google Scholar · View at Scopus
  173. K. Wimalasena, “Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry,” Medicinal Research Reviews, vol. 31, no. 4, pp. 483–519, 2011. View at Publisher · View at Google Scholar · View at Scopus
  174. M. B. Larsen, M. S. Sonders, O. V. Mortensen, G. A. Larson, N. R. Zahniser, and S. G. Amara, “Dopamine transport by the serotonin transporter: a mechanistically distinct mode of substrate translocation,” The Journal of Neuroscience, vol. 31, no. 17, pp. 6605–6615, 2011. View at Publisher · View at Google Scholar · View at Scopus
  175. S. M. Parsons, “Transport mechanisms in acetylcholine and monoamine storage,” The FASEB Journal, vol. 14, no. 15, pp. 2423–2434, 2000. View at Publisher · View at Google Scholar · View at Scopus
  176. B. Gasnier, “The loading of neurotransmitters into synaptic vesicles,” Biochimie, vol. 82, no. 4, pp. 327–337, 2000. View at Publisher · View at Google Scholar · View at Scopus
  177. M. Forgac, “Structure and properties of the vacuolar (H+)-ATPases,” The Journal of Biological Chemistry, vol. 274, no. 19, pp. 12951–12954, 1999. View at Publisher · View at Google Scholar · View at Scopus
  178. N. Nelson and W. R. Harvey, “Vacuolar and plasma membrane proton-adenosinetriphosphatases,” Physiological Reviews, vol. 79, no. 2, pp. 361–385, 1999. View at Google Scholar · View at Scopus
  179. D. Marazziti, S. Baroni, M. Catena Dell'Osso et al., “Presence and characterization of the dopamine transporter in human resting lymphocytes,” Neurochemical Research, vol. 33, no. 6, pp. 1011–1016, 2008. View at Publisher · View at Google Scholar · View at Scopus
  180. J. Mill, P. Asherson, C. Browes, U. D'Souza, and I. Craig, “Expression of the dopamine transporter gene is regulated by the 3′ UTR VNTR: Evidence from brain and lymphocytes using quantitative RT-PCR,” American Journal of Medical Genetics—Neuropsychiatric Genetics, vol. 114, no. 8, pp. 975–979, 2002. View at Publisher · View at Google Scholar · View at Scopus
  181. F. W. Lohoff, J. P. Dahl, T. N. Ferraro et al., “Variations in the vesicular monoamine transporter 1 gene (VMAT1/SLC18A1) are associated with bipolar I disorder,” Neuropsychopharmacology, vol. 31, no. 12, pp. 2739–2747, 2006. View at Publisher · View at Google Scholar · View at Scopus
  182. F. W. Lohoff, R. Hodge, S. Narasimhan et al., “Functional genetic variants in the vesicular monoamine transporter 1 modulate emotion processing,” Molecular Psychiatry, vol. 19, no. 1, pp. 129–139, 2014. View at Publisher · View at Google Scholar · View at Scopus
  183. E. Y. T. Chien, W. Liu, Q. Zhao et al., “Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist,” Science, vol. 330, no. 6007, pp. 1091–1095, 2010. View at Publisher · View at Google Scholar · View at Scopus
  184. V. Olivares-Illana, R. Arreola, A. Gómez-Poyou, and R. Pérez-Montfort, “Proteins and drug discovery (development),” in Advances in Protien Physical Chemistry, E. García-Hernández and D. A. Fernández-Velasco, Eds., p. 501, Transworld Research Network, Thiruvananthapuram, India, 1st edition, 2008. View at Google Scholar
  185. M. J. Wasko, K. A. Pellegrene, J. D. Madura, and C. K. Surratt, “A role for fragment-based drug design in developing novel lead compounds for central nervous system targets,” Frontiers in Neurology, vol. 6, article 197, 2015. View at Publisher · View at Google Scholar · View at Scopus
  186. R. Pacheco, C. E. Prado, M. J. Barrientos, and S. Bernales, “Role of dopamine in the physiology of T-cells and dendritic cells,” Journal of Neuroimmunology, vol. 216, no. 1-2, pp. 8–19, 2009. View at Publisher · View at Google Scholar · View at Scopus
  187. M. Cosentino, F. Marino, and G. J. M. Maestroni, “Sympathoadrenergic modulation of hematopoiesis: a review of available evidence and of therapeutic perspectives,” Frontiers in Cellular Neuroscience, vol. 9, article 302, 2015. View at Publisher · View at Google Scholar · View at Scopus
  188. A. Spiegel, A. Kalinkovich, S. Shivtiel, O. Kollet, and T. Lapidot, “Stem cell regulation via dynamic interactions of the nervous and immune systems with the microenvironment,” Cell Stem Cell, vol. 3, no. 5, pp. 484–492, 2008. View at Publisher · View at Google Scholar · View at Scopus
  189. G. J. M. Maestroni, A. Conti, and E. Pedrinis, “Effect of adrenergic agents on hematopoiesis after syngeneic bone marrow transplantation in mice,” Blood, vol. 80, no. 5, pp. 1178–1182, 1992. View at Google Scholar · View at Scopus
  190. A. Spiegel, S. Shivtiel, A. Kalinkovich et al., “Catecholaminergic neurotransmitters regulate migration and repopulation of immature human CD34+ cells through Wnt signaling,” Nature Immunology, vol. 8, no. 10, pp. 1123–1131, 2007. View at Publisher · View at Google Scholar · View at Scopus
  191. M. Cosentino, M. Ferrari, N. Kustrimovic, E. Rasini, and F. Marino, “Influence of dopamine receptor gene polymorphisms on circulating T lymphocytes: a pilot study in healthy subjects,” Human Immunology, vol. 76, no. 10, pp. 747–752, 2015. View at Publisher · View at Google Scholar · View at Scopus
  192. C. Sarkar, D. Chakroborty, P. S. Dasgupta, and S. Basu, “Dopamine is a safe antiangiogenic drug which can also prevent 5-fluorouracil induced neutropenia,” International Journal of Cancer, vol. 137, no. 3, pp. 744–749, 2015. View at Publisher · View at Google Scholar · View at Scopus
  193. L. Pavon, M. Jiménez-Martínez, and M. Garces-Alvarez, Inmunología Molecular, Celular y Traslacional, Kluwer Academic Publishers, Philadelphia, Pa, USA, 2016.
  194. M. Cosentino, F. Marino, R. Bombelli, M. Ferrari, S. Lecchini, and G. Frigo, “Endogenous catecholamine synthesis, metabolism, storage and uptake in human neutrophils,” Life Sciences, vol. 64, no. 11, pp. 975–981, 1999. View at Publisher · View at Google Scholar · View at Scopus
  195. C. Wenisch, B. Parschalk, A. Weiss et al., “High-dose catecholamine treatment decreases polymorphonuclear leukocyte phagocytic capacity and reactive oxygen production,” Clinical and Diagnostic Laboratory Immunology, vol. 3, no. 4, pp. 423–428, 1996. View at Google Scholar · View at Scopus
  196. S. Sookhai, J. H. Wang, M. McCourt, D. O'Connell, and H. P. Redmond, “Dopamine induces neutrophil apoptosis through a dopamine D-1 receptor-independent mechanism,” Surgery, vol. 126, no. 2, pp. 314–322, 1999. View at Publisher · View at Google Scholar · View at Scopus
  197. S. Sookhai, J. H. Wang, D. Winter, C. Power, W. Kirwan, and H. P. Redmond, “Dopamine attenuates the chemoattractant effect of interleukin-8: a novel role in the systemic inflammatory response syndrome,” Shock, vol. 14, no. 3, pp. 295–299, 2000. View at Publisher · View at Google Scholar · View at Scopus
  198. B. Trabold, M. Gruber, and D. Fröhlich, “Functional and phenotypic changes in polymorphonuclear neutrophils induced by catecholamines,” Scandinavian Cardiovascular Journal, vol. 41, no. 1, pp. 59–64, 2007. View at Publisher · View at Google Scholar · View at Scopus
  199. M. Cosentino, R. Bombelli, M. Ferrari et al., “HPLC-ED measurement of endogenous catecholamines in human immune cells and hematopoietic cell lines,” Life Sciences, vol. 68, no. 3, pp. 283–295, 2000. View at Publisher · View at Google Scholar · View at Scopus
  200. R. A. Ali, M. A. Qureshi, and F. M. McCorkle, “Profile of chicken macrophage functions after exposure to catecholamines in vitro,” Immunopharmacology and Immunotoxicology, vol. 16, no. 4, pp. 611–625, 1994. View at Publisher · View at Google Scholar · View at Scopus
  201. G. Haskó, C. Szabó, K. Merkel et al., “Modulation of lipopolysaccharide-induced tumor necrosis factor-α and nitric oxide production by dopamine receptor agonists and antagonists in mice,” Immunology Letters, vol. 49, no. 3, pp. 143–147, 1996. View at Publisher · View at Google Scholar · View at Scopus
  202. F. Gomez, P. Ruiz, F. Briceño, C. Rivera, and R. Lopez, “Macrophage Fcγ receptors expression is altered by treatment with dopaminergic drugs,” Clinical Immunology, vol. 90, no. 3, pp. 375–387, 1999. View at Publisher · View at Google Scholar · View at Scopus
  203. J. Bergquist, B. Ohlsson, and A. Tarkowski, “Nuclear factor-kappa B is involved in the catecholaminergic suppression of immunocompetent cells,” Annals of the New York Academy of Sciences, vol. 917, pp. 281–289, 2000. View at Google Scholar · View at Scopus
  204. G. Haskó, C. Szabó, Z. H. Németh, and E. A. Deitch, “Dopamine suppresses IL-12 p40 production by lipopolysaccharide-stimulated macrophages via a β-adrenoceptor-mediated mechanism,” Journal of Neuroimmunology, vol. 122, no. 1-2, pp. 34–39, 2002. View at Publisher · View at Google Scholar · View at Scopus
  205. O. Rohr, B. E. Sawaya, D. Lecestre, D. Aunis, and E. Schaeffer, “Dopamine stimulates expression of the human immunodeficiency virus type 1 via NF-κB in cells of the immune system,” Nucleic Acids Research, vol. 27, no. 16, pp. 3291–3299, 1999. View at Publisher · View at Google Scholar · View at Scopus
  206. E. A. Berger, P. M. Murphy, and J. M. Farber, “Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease,” Annual Review of Immunology, vol. 17, pp. 657–700, 1999. View at Publisher · View at Google Scholar · View at Scopus
  207. J. Wang, K. Crawford, M. Yuan, H. Wang, P. R. Gorry, and D. Gabuzda, “Regulation of CC chemokine receptor 5 and CD4 expression and human immunodeficiency virus type 1 replication in human macrophages and microglia by T helper type 2 cytokines,” Journal of Infectious Diseases, vol. 185, no. 7, pp. 885–897, 2002. View at Publisher · View at Google Scholar · View at Scopus
  208. S. Sozzani, S. Ghezzi, G. Iannolo et al., “Interleukin 10 increases CCR5 expression and HIV infection in human monocytes,” The Journal of Experimental Medicine, vol. 187, no. 3, pp. 439–444, 1998. View at Publisher · View at Google Scholar · View at Scopus
  209. P. J. Gaskill, H. H. Yano, G. V. Kalpana, J. A. Javitch, and J. W. Berman, “Dopamine receptor activation increases HIV entry into primary human macrophages,” PLoS ONE, vol. 9, no. 9, Article ID e108232, 2014. View at Publisher · View at Google Scholar · View at Scopus
  210. J. Bergquist and J. Silberring, “Identification of catecholamines in the immune system by electrospray ionization mass spectrometry,” Rapid Communications in Mass Spectrometry, vol. 12, no. 11, pp. 683–688, 1998. View at Publisher · View at Google Scholar · View at Scopus
  211. Y. H. Qiu, Y. P. Peng, J. M. Jiang, and J. J. Wang, “Expression of tyrosine hydroxylase in lymphocytes and effect of endogenous catecholamines on lymphocyte function,” Neuroimmunomodulation, vol. 11, no. 2, pp. 75–83, 2004. View at Google Scholar
  212. A. Ricci, L. Chiandussi, M. Schena, D. Schiavone, F. Veglio, and F. Amenta, “Dopamine D5 receptor expression is unchanged in peripheral blood lymphocytes in essential hypertension,” Clinical and Experimental Hypertension, vol. 17, no. 8, pp. 1157–1172, 1995. View at Publisher · View at Google Scholar · View at Scopus
  213. M. Levite, Y. Chowers, Y. Ganor, M. Besser, R. Hershkovits, and L. Cahalon, “Dopamine interacts directly with its D3 and D2 receptors on normal human T cells, and activates β1 integrin function,” European Journal of Immunology, vol. 31, no. 12, pp. 3504–3512, 2001. View at Publisher · View at Google Scholar · View at Scopus
  214. B. Saha, A. C. Mondal, S. Basu, and P. S. Dasgupta, “Circulating dopamine level, in lung carcinoma patients, inhibits proliferation and cytotoxicity of CD4+ and CD8+ T cells by D1 dopamine receptors: an in vitro analysis,” International Immunopharmacology, vol. 1, no. 7, pp. 1363–1374, 2001. View at Publisher · View at Google Scholar · View at Scopus
  215. B. Saha, A. C. Mondal, J. Majumder, S. Basu, and P. S. Dasgupta, “Physiological concentrations of dopamine inhibit the proliferation and cytotoxicity of human CD4+ and CD8+ T cells in vitro: a receptor-mediated mechanism,” NeuroImmunoModulation, vol. 9, no. 1, pp. 23–33, 2001. View at Publisher · View at Google Scholar · View at Scopus
  216. C.-W. Tsao, Y.-S. Lin, and J.-T. Cheng, “Effect of dopamine on immune cell proliferation in mice,” Life Sciences, vol. 61, no. 24, pp. PL361–PL371, 1997. View at Publisher · View at Google Scholar · View at Scopus
  217. L. Carr, A. Tucker, and R. Fernandez-Botran, “In vivo administration of l-dopa or dopamine decreases the number of splenic IFNγ-producing cells,” Journal of Neuroimmunology, vol. 137, no. 1-2, pp. 87–93, 2003. View at Publisher · View at Google Scholar · View at Scopus
  218. K. Nakagome, M. Imamura, H. Okada et al., “Dopamine D1-like receptor antagonist attenuates Th17-mediated immune response and ovalbumin antigen-induced neutrophilic airway inflammation,” Journal of Immunology, vol. 186, no. 10, pp. 5975–5982, 2011. View at Publisher · View at Google Scholar · View at Scopus
  219. J. M. Cook-Mills, R. L. Cohen, R. L. Perlman, and D. A. Chambers, “Inhibition of lymphocyte activation by catecholamines: evidence for a non-classical mechanism of catecholamine action,” Immunology, vol. 85, no. 4, pp. 544–549, 1995. View at Google Scholar · View at Scopus
  220. T. Mori, K. Kabashima, S. Fukamachi et al., “D1-like dopamine receptors antagonist inhibits cutaneous immune reactions mediated by Th2 and mast cells,” Journal of Dermatological Science, vol. 71, no. 1, pp. 37–44, 2013. View at Publisher · View at Google Scholar · View at Scopus
  221. P. S. Dasgupta and T. Lahiri, “Antitumor effect of i.p. dopamine in mice bearing Ehrlich ascites carcinoma,” Journal of Cancer Research and Clinical Oncology, vol. 113, no. 4, pp. 363–368, 1987. View at Publisher · View at Google Scholar · View at Scopus
  222. S. Basu, P. S. Dasgupta, M. R. Ray, and T. Lahiri, “Stimulation of NK activity in Ehrlich ascites carcinoma-bearing mice following dopamine treatment,” Biogenic Amines, vol. 8, article 7, 1992. View at Google Scholar
  223. M. A. T. Teunis, C. J. Heijnen, A. R. Cools, and A. Kavelaars, “Reduced splenic natural killer cell activity in rats with a hyperreactive dopaminergic system,” Psychoneuroendocrinology, vol. 29, no. 8, pp. 1058–1064, 2004. View at Publisher · View at Google Scholar · View at Scopus
  224. K. S. Madden, V. M. Sanders, and D. L. Felten, “Catecholamine influences and sympathetic neural modulation of immune responsiveness,” Annual Review of Pharmacology and Toxicology, vol. 35, pp. 417–448, 1995. View at Publisher · View at Google Scholar · View at Scopus
  225. Y. Huang, Z. Liu, X. Q. Wang, and Y. H. Qiu, “A dysfunction of CD4+ T lymphocytes in peripheral immune system of Parkinson's disease model mice,” Zhongguo Ying Yong Sheng Li Xue Za Zhi, vol. 30, no. 6, pp. 567–576, 2014. View at Google Scholar
  226. S. Basu, P. S. Dasgupta, and J. R. Chowdhury, “Enhanced tumor growth in brain dopamine-depleted mice following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment,” Journal of Neuroimmunology, vol. 60, no. 1-2, pp. 1–8, 1995. View at Publisher · View at Google Scholar · View at Scopus
  227. B. Deleplanque, S. Vitiello, M. Le Moal, and P. J. Neveu, “Modulation of immune reactivity by unilateral striatal and mesolimbic dopaminergic lesions,” Neuroscience Letters, vol. 166, no. 2, pp. 216–220, 1994. View at Publisher · View at Google Scholar · View at Scopus
  228. P. Barbanti, G. Fabbrini, A. Ricci et al., “Reduced density of dopamine D2-like receptors on peripheral blood lymphocytes in Alzheimer's disease,” Mechanisms of Ageing and Development, vol. 120, no. 1–3, pp. 65–75, 2000. View at Publisher · View at Google Scholar · View at Scopus
  229. M. Cosentino, C. Colombo, M. Mauri et al., “Expression of Apoptosis-related Proteins and of mRNA for dopaminergic receptors in peripheral blood mononuclear cells from patients with Alzheimer disease,” Alzheimer Disease and Associated Disorders, vol. 23, no. 1, pp. 88–90, 2009. View at Publisher · View at Google Scholar · View at Scopus
  230. F. Giubilei, C. Calderaro, G. Antonini et al., “Increased lymphocyte dopamine β-hydroxylase immunoreactivity in Alzheimer's disease: compensatory response to cholinergic deficit?” Dementia and Geriatric Cognitive Disorders, vol. 18, no. 3-4, pp. 338–341, 2004. View at Publisher · View at Google Scholar · View at Scopus
  231. Y. T. Kwak, M.-S. Koo, C.-H. Choi, and I. N. Sunwoo, “Change of dopamine receptor mRNA expression in lymphocyte of schizophrenic patients,” BMC Medical Genetics, vol. 2, article 3, 2001. View at Publisher · View at Google Scholar · View at Scopus
  232. T. Ilani, D. Ben-Shachar, R. D. Strous et al., “A peripheral marker for schizophrenia: increased levels of D3 dopamine receptor mRNA in blood lymphocytes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 2, pp. 625–628, 2001. View at Publisher · View at Google Scholar · View at Scopus
  233. E. M. Boneberg, E. von Seydlitz, K. Pröpster, H. Watzl, B. Rockstroh, and H. Illges, “D3 dopamine receptor mRNA is elevated in T cells of schizophrenic patients whereas D4 dopamine receptor mRNA is reduced in CD4+-T cells,” Journal of Neuroimmunology, vol. 173, no. 1-2, pp. 180–187, 2006. View at Publisher · View at Google Scholar
  234. M. Vogel, S. Pfeifer, R. T. Schaub et al., “Decreased levels of dopamine D3 receptor mRNA in schizophrenic and bipolar patients,” Neuropsychobiology, vol. 50, no. 4, pp. 305–310, 2004. View at Publisher · View at Google Scholar · View at Scopus
  235. Á. Zvara, G. Szekeres, Z. Janka et al., “Over-expression of dopamine D2 receptor and inwardly rectifying potassium channel genes in drug-naive schizophrenic peripheral blood lymphocytes as potential diagnostic markers,” Disease Markers, vol. 21, no. 2, pp. 61–69, 2005. View at Publisher · View at Google Scholar · View at Scopus
  236. M. Urhan-Kucuk, M. E. Erdal, M. E. Ozen, S. Kul, and H. Herken, “Is the dopamine D3 receptor mRNA on blood lymphocytes help to for identification and subtyping of schizophrenia?” Molecular Biology Reports, vol. 38, no. 4, pp. 2569–2572, 2011. View at Publisher · View at Google Scholar · View at Scopus
  237. Y. Cui, V. Prabhu, T. B. Nguyen, B. K. Yadav, and Y.-C. Chung, “The mRNA expression status of dopamine receptor D2, dopamine receptor D3 and DARPP-32 in T lymphocytes of patients with early psychosis,” International Journal of Molecular Sciences, vol. 16, no. 11, pp. 26677–26686, 2015. View at Publisher · View at Google Scholar · View at Scopus
  238. F. Marino and M. Cosentino, “Multiple sclerosis: repurposing dopaminergic drugs for MS—the evidence mounts,” Nature Reviews Neurology, vol. 12, no. 4, pp. 191–192, 2016. View at Publisher · View at Google Scholar
  239. J. S. Tzartos, M. A. Friese, M. J. Craner et al., “Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis,” The American Journal of Pathology, vol. 172, no. 1, pp. 146–155, 2008. View at Publisher · View at Google Scholar · View at Scopus
  240. M. Cosentino, M. Zaffaroni, M. Ferrari et al., “Interferon-γ and interferon-β affect endogenous catecholamines in human peripheral blood mononuclear cells: implications for multiple sclerosis,” Journal of Neuroimmunology, vol. 162, no. 1-2, pp. 112–121, 2005. View at Publisher · View at Google Scholar · View at Scopus
  241. M. Cosentino, M. Zaffaroni, and F. Marino, “Levels of mRNA for dopaminergic receptor D5 in circulating lymphocytes may be associated with subsequent response to interferon-β in patients with multiple sclerosis,” Journal of Neuroimmunology, vol. 277, no. 1-2, pp. 193–196, 2014. View at Publisher · View at Google Scholar · View at Scopus
  242. E. Bałkowiec-Iskra, I. Kurkowska-Jastrzebska, I. Joniec et al., “MPTP-induced central dopamine depletion exacerbates experimental autoimmune encephalomyelitis (EAE) in C57BL mice,” Inflammation Research, vol. 56, no. 8, pp. 311–317, 2007. View at Publisher · View at Google Scholar · View at Scopus
  243. T. Lowin and R. H. Straub, “Synovial fibroblasts integrate inflammatory and neuroendocrine stimuli to drive rheumatoid arthritis,” Expert Review of Clinical Immunology, vol. 11, no. 10, pp. 1069–1071, 2015. View at Publisher · View at Google Scholar · View at Scopus
  244. S. Capellino, M. Cosentino, A. Luini et al., “Increased expression of dopamine receptors in synovial fibroblasts from patients with rheumatoid arthritis: inhibitory effects of dopamine on interleukin-8 and interleukin-6,” Arthritis and Rheumatology, vol. 66, no. 10, pp. 2685–2693, 2014. View at Publisher · View at Google Scholar · View at Scopus
  245. M. Levite, “Dopamine and T cells: dopamine receptors and potent effects on T cells, dopamine production in T cells, and abnormalities in the dopaminergic system in T cells in autoimmune, neurological and psychiatric diseases,” Acta Physiologica, vol. 216, no. 1, pp. 42–89, 2016. View at Publisher · View at Google Scholar · View at Scopus
  246. K. Nakano, K. Yamaoka, K. Hanami et al., “Dopamine induces IL-6-dependent IL-17 production via D1-like receptor on CD4 naive T cells and D1-like receptor antagonist SCH-23390 inhibits cartilage destruction in a human rheumatoid arthritis/SCID mouse chimera model,” Journal of Immunology, vol. 186, no. 6, pp. 3745–3752, 2011. View at Publisher · View at Google Scholar · View at Scopus
  247. M. Mobini, Z. Kashi, A. R. Mohammad Pour, and E. Adibi, “The effect of cabergoline on clinical and laboratory findings in active rheumatoid arthritis,” Iranian Red Crescent Medical Journal, vol. 13, no. 10, pp. 749–750, 2011. View at Google Scholar · View at Scopus
  248. R. Pacheco, F. Contreras, and M. Zouali, “The dopaminergic system in autoimmune diseases,” Frontiers in Immunology, vol. 5, article 117, 2014. View at Publisher · View at Google Scholar · View at Scopus
  249. S. J. Chadban and R. C. Atkins, “Glomerulonephritis,” The Lancet, vol. 365, no. 9473, pp. 1797–1806, 2005. View at Publisher · View at Google Scholar · View at Scopus
  250. T. Hussain and M. F. Lokhandwala, “Renal dopamine receptor function in hypertension,” Hypertension, vol. 32, no. 2, pp. 187–197, 1998. View at Publisher · View at Google Scholar · View at Scopus
  251. S. Hoeger, U. Gottmann, Z. Liu et al., “Dopamine treatment in brain-dead rats mediates anti-inflammatory effects: the role of hemodynamic stabilization and D-receptor stimulation,” Transplant International, vol. 20, no. 9, pp. 790–799, 2007. View at Publisher · View at Google Scholar · View at Scopus
  252. S. Hoeger, A. Reisenbuechler, U. Gottmann et al., “Donor dopamine treatment in brain dead rats is associated with an improvement in renal function early after transplantation and a reduction in renal inflammation,” Transplant International, vol. 21, no. 11, pp. 1072–1080, 2008. View at Publisher · View at Google Scholar · View at Scopus
  253. S. Kapper, G. Beck, S. Riedel et al., “Modulation of chemokine production and expression of adhesion molecules in renal tubular epithelial and endothelial cells by catecholamines,” Transplantation, vol. 74, no. 2, pp. 253–260, 2002. View at Publisher · View at Google Scholar · View at Scopus
  254. D. Chakroborty, C. Sarkar, B. Basu, P. S. Dasgupta, and S. Basu, “Catecholamines regulate tumor angiogenesis,” Cancer Research, vol. 69, no. 9, pp. 3727–3730, 2009. View at Publisher · View at Google Scholar · View at Scopus
  255. H. F. Dvorak, “Angiogenesis: update 2005,” Journal of Thrombosis and Haemostasis, vol. 3, no. 8, pp. 1835–1842, 2005. View at Publisher · View at Google Scholar · View at Scopus
  256. D. D. Feng, W. Cai, and X. Chen, “The associations between Parkinson's disease and cancer: the plot thickens,” Translational Neurodegeneration, vol. 4, article 20, 2015. View at Publisher · View at Google Scholar
  257. C. Sarkar, B. Basu, D. Chakroborty, P. S. Dasgupta, and S. Basu, “The immunoregulatory role of dopamine: an update,” Brain, Behavior, and Immunity, vol. 24, no. 4, pp. 525–528, 2010. View at Publisher · View at Google Scholar · View at Scopus
  258. R. Hodgson, H. J. Wildgust, and C. J. Bushe, “Cancer and schizophrenia: is there a paradox?” Journal of Psychopharmacology, vol. 24, no. 4, supplement, pp. 51–60, 2010. View at Google Scholar · View at Scopus
  259. M. Asada, S. Ebihara, Y. Numachi et al., “Reduced tumor growth in a mouse model of schizophrenia, lacking the dopamine transporter,” International Journal of Cancer, vol. 123, no. 3, pp. 511–518, 2008. View at Publisher · View at Google Scholar · View at Scopus
  260. J. A. Driver, G. Logroscino, J. E. Buring, J. M. Gaziano, and T. Kurth, “A prospective cohort study of cancer incidence following the diagnosis of Parkinson's disease,” Cancer Epidemiology Biomarkers and Prevention, vol. 16, no. 6, pp. 1260–1265, 2007. View at Publisher · View at Google Scholar · View at Scopus
  261. E. Sachlos, R. M. Risueño, S. Laronde et al., “Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells,” Cell, vol. 149, no. 6, pp. 1284–1297, 2012. View at Publisher · View at Google Scholar · View at Scopus
  262. C. Sarkar, D. Chakroborty, R. B. Mitra, S. Banerjee, P. S. Dasgupta, and S. Basu, “Dopamine in vivo inhibits VEGF-induced phosphorylation of VEGFR-2, MAPK, and focal adhesion kinase in endothelial cells,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 287, no. 4, pp. H1554–H1560, 2004. View at Publisher · View at Google Scholar · View at Scopus
  263. S. Basu, J. A. Nagy, S. Pal et al., “The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor,” Nature Medicine, vol. 7, no. 5, pp. 569–574, 2001. View at Publisher · View at Google Scholar · View at Scopus
  264. D. Chakroborty, C. Sarkar, R. B. Mitra, S. Banerjee, P. S. Dasgupta, and S. Basu, “Depleted dopamine in gastric cancer tissues: dopamine treatment retards growth of gastric cancer by inhibiting angiogenesis,” Clinical Cancer Research, vol. 10, no. 13, pp. 4349–4356, 2004. View at Publisher · View at Google Scholar · View at Scopus
  265. S. Ganguly, B. Basu, S. Shome et al., “Dopamine, by acting through Its D2 receptor, inhibits insulin-like growth factor-I (IGF-I)-induced gastric cancer cell proliferation via up-regulation of Krüppel-like factor 4 through down-regulation of IGF-IR and AKT phosphorylation,” American Journal of Pathology, vol. 177, no. 6, pp. 2701–2707, 2010. View at Publisher · View at Google Scholar · View at Scopus
  266. S. Basu, C. Sarkar, D. Chakroborty et al., “Ablation of peripheral dopaminergic nerves stimulates malignant tumor growth by inducing vascular permeability factor/vascular endothelial growth factor-mediated angiogenesis,” Cancer Research, vol. 64, no. 16, pp. 5551–5555, 2004. View at Publisher · View at Google Scholar · View at Scopus
  267. D. Chakroborty, C. Sarkar, H. Yu et al., “Dopamine stabilizes tumor blood vessels by up-regulating angiopoietin 1 expression in pericytes and Krüppel-like factor-2 expression in tumor endothelial cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 51, pp. 20730–20735, 2011. View at Publisher · View at Google Scholar · View at Scopus
  268. F. Lopez Vicchi, G. M. Luque, B. Brie, J. P. Nogueira, I. Garcia Tornadu, and D. Becu-Villalobos, “Dopaminergic drugs in type 2 diabetes and glucose homeostasis,” Pharmacological Research, vol. 109, pp. 74–80, 2016. View at Publisher · View at Google Scholar · View at Scopus
  269. American Diabetes Association, “Diagnosis and classification of diabetes mellitus,” Diabetes Care, vol. 29, supplement 1, pp. S43–S48, 2006. View at Google Scholar
  270. B. J. Davis and P. H. Smith, “Effects of substantia nigra lesions on the volumes of A, B, and D cells and the content of insulin and glucagon in the rat pancreas,” Diabetologia, vol. 28, no. 10, pp. 756–762, 1985. View at Publisher · View at Google Scholar · View at Scopus
  271. B. Rubi, S. Ljubicic, S. Pournourmohammadi et al., “Dopamine D2-like receptors are expressed in pancreatic beta cells and mediate inhibition of insulin secretion,” The Journal of Biological Chemistry, vol. 280, no. 44, pp. 36824–36832, 2005. View at Publisher · View at Google Scholar · View at Scopus
  272. Y. Zhang, R. Zheng, X. Meng, L. Wang, L. Liu, and Y. Gao, “Pancreatic endocrine effects of dopamine receptors in human islet cells,” Pancreas, vol. 44, no. 6, pp. 925–929, 2015. View at Publisher · View at Google Scholar · View at Scopus
  273. Y. Chen, F. Hong, H. Chen et al., “Distinctive expression and cellular distribution of dopamine receptors in the pancreatic islets of rats,” Cell and Tissue Research, vol. 357, no. 3, pp. 597–606, 2014. View at Publisher · View at Google Scholar · View at Scopus
  274. E. Shankar, K. T. Santhosh, and C. S. Paulose, “Dopaminergic regulation of glucose-induced insulin secretion through dopamine D2 receptors in the pancreatic islets in vitro,” IUBMB Life, vol. 58, no. 3, pp. 157–163, 2006. View at Publisher · View at Google Scholar · View at Scopus
  275. K. Melkersson, A. Khan, A. Hilding, and A. L. Hulting, “Different effects of antipsychotic drugs on insulin release in vitro,” European Neuropsychopharmacology, vol. 11, no. 5, pp. 327–332, 2001. View at Google Scholar
  276. W. Wu, J. Shang, Y. Feng et al., “Identification of glucose-dependent insulin secretion targets in pancreatic β cells by combining defined-mechanism compound library screening and siRNA gene silencing,” Journal of Biomolecular Screening, vol. 13, no. 2, pp. 128–134, 2008. View at Publisher · View at Google Scholar · View at Scopus
  277. I. García-Tornadú, A. M. Ornstein, A. Chamson-Reig et al., “Disruption of the dopamine D2 receptor impairs insulin secretion and causes glucose intolerance,” Endocrinology, vol. 151, no. 4, pp. 1441–1450, 2010. View at Publisher · View at Google Scholar · View at Scopus
  278. A. Ustione, D. W. Piston, and P. E. Harris, “Minireview: dopaminergic regulation of insulin secretion from the pancreatic islet,” Molecular Endocrinology, vol. 27, no. 8, pp. 1198–1207, 2013. View at Publisher · View at Google Scholar · View at Scopus
  279. K. Hashimoto, T. Inoue, T. Higashi et al., “Dopamine D1-like receptor antagonist, SCH23390, exhibits a preventive effect on diabetes mellitus that occurs naturally in NOD mice,” Biochemical and Biophysical Research Communications, vol. 383, no. 4, pp. 460–463, 2009. View at Publisher · View at Google Scholar · View at Scopus
  280. A. Goodarzi, N. Vousooghi, M. Sedaghati, A. Mokri, and M.-R. Zarrindast, “Dopamine receptors in human peripheral blood lymphocytes: changes in mRNA expression in opioid addiction,” European Journal of Pharmacology, vol. 615, no. 1–3, pp. 218–222, 2009. View at Publisher · View at Google Scholar · View at Scopus
  281. N. D. Volkow, G.-J. Wang, J. S. Fowler, and D. Tomasi, “Addiction circuitry in the human brain,” Annual Review of Pharmacology and Toxicology, vol. 52, pp. 321–336, 2012. View at Publisher · View at Google Scholar · View at Scopus
  282. C. Czermak, M. Lehofer, H. Renger et al., “Dopamine receptor D3 mRNA expression in human lymphocytes is negatively correlated with the personality trait of persistence,” Journal of Neuroimmunology, vol. 150, no. 1-2, pp. 145–149, 2004. View at Publisher · View at Google Scholar · View at Scopus